Primary pulmonary hypertension and cor pulmonale

Cardiology in Review

Volumn 10, Issue 5, 2002, Pages 265-278

  Lehrman, Stuart ^a   Romano, Patricia ^a   Frishman, William ^a   Rashid, Amber ^a   Dobkin, Jay ^a   Reichel, Joseph ^a  

^a WESTCHESTER MEDICAL CENTER   (United States)

Author keywords

Bosentan; Cor pulmonale; Postacyclin; Primary pulmonary hypertension

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE; AMINOREX; ANOREXIGENIC AGENT; ANTICOAGULANT AGENT; BERAPROST; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; DEXFENFLURAMINE; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ENDOTHELIN RECEPTOR ANTAGONIST; HYDRALAZINE; ILOPROST; MILRINONE; MONOCROTALINE; NIFEDIPINE; NITRIC OXIDE; ORAL CONTRACEPTIVE AGENT; PROSTACYCLIN; SILDENAFIL; TRIPTOLIDE; TRYPTOPHAN; UNINDEXED DRUG; VASODILATOR AGENT; WARFARIN; ZAPRINAST;

ANTICOAGULANT THERAPY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; COR PULMONALE; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DIURETIC THERAPY; DRUG INDUCED DISEASE; DYSPNEA; EDEMA; HEADACHE; HEART FAILURE; HUMAN; LUNG DISEASE; NAUSEA; OXYGEN THERAPY; PATHOGENESIS; PHLEBOTOMY; POLYCYTHEMIA; PULMONARY HYPERTENSION; SURVIVAL RATE; THORAX PAIN; THROMBOEMBOLISM;

EID: 0036734610     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045415-200209000-00003     Document Type: Article

References (125)

1. Primary pulmonary hypertension: A national prospective study
2. Familial primary pulmonary hypertension: Clinical patterns
3. Uber sklerose der lungenarterian
4. Primary pulmonary hypertension
5. Histopathology of primary pulmonary hypertension
6. Histopathology of pulmonary hypertension: A qualitative and quantitative study of pulmonary blood vessels from 58 patients in National Heart, Lung and Blood Institute, Primary Pulmonary Hypertension Registry
7. Primary pulmonary hypertension: A pathologic study of the lung vessels in 156 clinically diagnosed cases
8. Heterogeneity of pathologic lesion in familial primary pulmonary hypertension
9. Primary pulmonary hypertension: Update on pathogenesis and novel therapies
10. The response of the pulmonary circulation to acetylcholine, calcitonin gene-related peptide, substance P and oral nicardipine in patients with primary pulmonary hypertension
11. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension
12. Increased plasma endothelin-1 in pulmonary hypertension: Marker or mediator of disease?
13. A novel potent vasoconstrictor peptide produced by vascular endothelial cells
14. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension
15. Pulmonary hypertension in patients using oral contraceptives: A report of six cases
16. Aminorex pulmonary hypertension
17. Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates: Implications for primary pulmonary hypertension
18. Pulmonary hypertension and dexfenfluramine
19. Anorexigenics and pulmonary hypertension in the United States: Results from the Surveillance of North American Pulmonary Hypertension
20. Pulmonary disease associated with L-tryptophan-induced eosinophilic myalgia syndrome: Clinical and pathology features
21. Pulmonary hypertension due to toxic oil syndrome: A clinicopathologic study
22. Pulmonary hypertension in female crack users
23. Pulmonary hypertension in polymyositis
24. Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis
25. Pulmonary hypertension in systemic lupus erythematosus
26. Primary pulmonary hypertension and cirrhosis: Are they related?
27. Pulmonary hypertension complicating portal hypertension: Prevalence and relation to splanchnic hemodynamics
28. Primary pulmonary hypertension associated with human immunodeficiency virus infection: A possible viral etiology for some forms of hypertensive arteriopathy
29. Pulmonary arterial distention and activity in phrenic nerve of anesthetized dogs
30. Restrictive ventilatory pattern in precapillary pulmonary hypertension
31. Antinuclear antibodies in primary pulmonary hypertension
32. Differentiation of patients with primary and thromboembolic pulmonary hypertension
33. Primary pulmonary hypertension: Case series from the United Kingdom
34. Survival in patients with primary pulmonary hypertension: Results from a national prospective registry
35. Primary pulmonary hypertension: Natural history and importance of thrombosis
36. The effect of vasodilator therapy on the clinical outcome of patients with primary pulmonary hypertension
37. The pathophysiology and management of primary pulmonary hypertension
38. Primary pulmonary hypertension: Case series from France
39. Vasodilators in primary pulmonary hypertension: Variability of long-term response
40. Magnitude and implications of spontaneous hemodynamic variability in primary pulmonary hypertension
41. Role of pharmacologic test in the treatment of primary pulmonary hypertension
42. Fatal outcome following nifedipine for pulmonary hypertensionr
43. Primary pulmonary hypertension: ACCP consensus statement
44. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation
45. Haemodynamic changes induced by prostacyclin in man
46. Modulation of human platelet: Adenylate cyclase by prostacyclin (Pgx)
47. The effect of prostacyclin (PGI2) on platelet behaviour, thrombus formation in vivo and bleeding time
48. Prostacyclin and prostaglandin E1 for severe idiopathic pulmonary artery hypertension
49. Comparative acute effects of adenosine and prostacyclin in primary pulmonary hypertension
50. Reduction in pulmonary vascular resistance with long term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension
51. Epoprostenolol (prostacyclin) and pulmonary hypertension
52. Treatment of primary pulmonary hypertension with continuous prostacyclin (epoprostenol)
53. Long term infusion of prostacyclin on exercise performance in patients with primary pulmonary hypertension
54. Randomized trial of conventional therapy alone (CT) vs conventional therapy + continuous infusions of prostacyclin (CT + PGI2) in primary pulmonary hypertension (PPH): A 12 week study
55. Epoprostenolol for treatment of pulmonary hyper-tension in patients with systemic lupus erythematosus
56. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: A randomized, controlled trial
57. Role of prostacyclin in the treatment of primary pulmonary hypertension
58. Aerosolised prostacyclin in adult respiratory distress syndrome
59. The acute effect of the synthetic prostacyclin analogue iloprost in primary pulmonary hypertension
60. Inhaled iloprost to treat severe pulmonary hypertension: An uncontrolled trial
61. Effects of long-term treatment with iloprost, a prostacyclin analogue on exercise tolerance in patients with primary pulmonary hypertension
62. Effects of iloprost inhalation on exercise capacity and ventilatory efficiency in patients with primary pulmonary hypertension
63. Long-term treatment of pulmonary hypertension with aerosolized iloprost
64. Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension
65. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue
66. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension
67. Effects of orally active prostacyclin analogue on survival of out-patients with primary pulmonary hypertension
68. The effect of high doses of calcium channel blockers on survival in primary pulmonary hypertension
69. Prediction of favourable responses to long-term vasodilator treatment of pulmonary hypertension by short-term administration of epoprostenol (prostacyclin) or nifedipine
70. High-dose titration of calcium channel blocking agents for primary pulmonary hyper-tension: Guidelines for short-term drug testing
71. The management of primary pulmonary hypertension
72. Nitric oxide release accounts for the biologic activity of endothelium-derived relaxing factor
73. Nitric oxide physiology, pathophysiology and pharmacology
74. Inhibition by nitric oxide and nitric oxide-producing vasodilators of DNA synthesis in vascular smooth muscle cells
75. Release of endothelin from the porcine aorta
76. Endothelium-derived relaxing factor and the pulmonary circulation
77. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension
78. Long term inhalation of NO for a patient with primary pulmonary hypertension
79. Additive effects of inhaled nitric oxide and intravenous milrinone in experimental pulmonary hypertension
80. Primary pulmonary hypertension: Natural history and the importance of thrombosis
81. The effect of anticoagulant therapy in primary and anorectic drug induced pulmonary hypertension
82. Antithrombotic therapy for venous thromboembolic disease
83. The use of aspirin in patients with primary pulmonary hypertension
84. Adenosine as a vasodilator in primary pulmonary hypertension
85. Basis for the selective reduction of pulmonary vascular resistance in humans during infusion of adenosine
86. Comparison of the effects of adenosine and nifedipine in pulmonary hypertension
87. Effects of adenosine in combination with calcium channel blockers in patients with primary pulmonary hypertension
88. Short-term pulmonary vasodilation with L-arginine in pulmonary hypertension
89. Differential systemic and pulmonary hemodynamic effects of L-arginine infusion in patients with coronary artery disease or primary pulmonary hypertension
90. Lack of beneficial effects of L-arginine infusion in primary pulmonary hypertension
91. Increased plasma serotonin in primary pulmonary hypertension
92. Serotonin and serotonin antagonism in cardiovascular and non-cardiovascular disease
93. Vasodilator therapy for primary pulmonary hypertension: Limitations and hazards
94. Acute hemodynamic effects of ketanserin in pulmonary hypertension secondary to systemic sclerosis
95. Plasma endothelin-1 levels, pulmonary hypertension, and lung fibrosis in patients with systemic sclerosis
96. Endothelin as a therapeutic target in the treatment of cardiovascular disease
97. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: A randomized placebo-controlled study
98. Chronic blockade of endothelin-A receptors with BQ-123 prevents hypoxia induced pulmonary hypertension and pulmonary vascular remodeling in rats
99. Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor
100. In vivo gene transfer of prepro-calcitonin gene-related peptide to the lung attenuates chronic hypoxia-induced pulmonary hypertension in the mouse
101. New approaches to pulmonary hypertension: Will therapies in mice work in humans?
102. Triptolide attenuates pulmonary arterial hypertension and neointimal formation in rats
103. Sildenafil can increase the response to inhaled nitric oxide
104. Viagra for impotence of pulmonary vasodilator therapy?
105. Sildenafil in primary pulmonary hypertension
106. Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension
107. Combined therapy with zaprinast and inhaled nitric oxide abolishes hypoxic pulmonary hypertension
108. Selective pulmonary vasodilation induced by aerosolized Zaprinast
109. Effects of intravenous Zaprinast and inhaled nitric oxide on pulmonary hemodynamics and gas exchange in an ovine model of acute respiratory distress syndrome
110. Effects of oxygen breathing on pulmonary vascular input impedance in patients with pulmonary hypertension
111. The short term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension
112. Definition of chronic cor pulmonale: A report of the expert committee
113. Pulmonary heart disease
114. Cor pulmonale
115. The normal adult pulmonary circulation
116. Primary pulmonary hypertension
117. Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension
118. Effects of long-term oxygen therapy on mortality and morbidity
119. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema: Report of the Medical Research Council Working Party
120. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: A clinical trial
121. Almitrine bimesylate and oxygen therapy in hypoxic cor pulmonale
122. Therapeutic application of calcium-channel antagonists for pulmonary hypertension
123. Effect of enalapril on renal profile and right ventricular dimensions in chronic cor pulmonale
124. Atrial natriuretic peptide and brain natriuretic peptide in cor pulmonale
125. Continuous home ambulatory intravenous inotropic drug therapy in severe heart failure: Safety and cost efficacy